AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells
Not Applicable
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: Sample collection
- Registration Number
- NCT04169022
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Brief Summary
AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality. Despite progress in the treatment of leukemic malignancies, especially the emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there remains a need to provide additional strategies for refractory/relapsing (R/R) patients
Aim of this study is to collect biological samples of AML patients in order to validate our Chimeric Antigen Receptor T-cells immunotherapy approach
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
- AML patients adults and pediatrics
Exclusion Criteria
- AML3
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description AML patients at relapse Sample collection AML patients at relapse after chemotherapy, targeted therapy or allograft AML patients at diagnosis Sample collection AML patients at diagnosis (except AML3)
- Primary Outcome Measures
Name Time Method IL1RAP protein expression 2 years Cytometry analysis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Besançon
🇫🇷Besançon, France